Apparently, late yesterday, Barvarian Nordic announced that Prostvac has failed to show efficacy in the Phase III PROSPECT trial of the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). Click here for Barvarian Nordic’s media release.
Filed under: Drugs in development, Management, Treatment | Tagged: Barvarian, mCRPC, Nordic, PROSPECT, Prostvac, trial |
This site uses Akismet to reduce spam. Learn how your comment data is processed.
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
Blog at WordPress.com. WP Designer.
THE "NEW" PROSTATE CANCER INFOLINK
This truly is disappointing. ProstVac sounded to me like a much less inconvenient treatment than Provenge. I had been hoping the trial would succeed.
I wonder what the thinking is now regarding why it failed?
Mark:
Perhaps a more relevant question (already raised by some experts) is: were the positive results of the Phase II trial from several years ago misleading for some definable reason?
Related to that, I was wondering if the Phase II sample set included an identifiable subset of patients who are particularly responsive. I want to emphasize that though it failed to show efficacy, the trial was not a failure. They monitored the immune response very closely, and we stand to learn a great deal about the biochemistry of the immune response. This “failure” may be the harbinger of the next success. It is worth recalling that Prostvac is still being explored (as far as I know) as a therapy combined with ipilimumab, combined with docetaxel for mHSPC, for active surveillance, and for biochemical recurrence.